FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for COMPLERA, a fixed-dose combination therapy for HIV-1 infection developed by Gilead Sciences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• COMPLERA (Emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)

Snippet

SUPPL AP for COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE)